tebnow← All categories
Category

Disease & Epidemiology

1265 articles indexed

FTC Settles with CVS Caremark Over Insulin Price Manipulation, Promises Major Savings for Patients

The Federal Trade Commission (FTC) has reached a settlement with CVS Caremark, a leading pharmacy benefit manager, following allegations that the company manipulated insulin prices and obstructed patient access to this critical diabetes medication. The settlement is projected to save Americans approximately $8.5 billion in out-of-pocket expenses over the next decade. CVS Caremark, a subsidiary of CVS Health, is required to implement significant changes in its operations with employers, health plans, and pharmacies to enhance transparency and affordability. The FTC's complaint highlighted a troubling rebate system employed by CVS Caremark, along with competitors Cigna’s Express Scripts and UnitedHealth’s Optum Rx. This system reportedly favored insulin, leading to inflated list prices that ultimately burdened patients financially. The settlement aims to rectify these practices, with the FTC estimating an additional $4.5 billion in savings for patients through improved pharmacy counter rebates. This development is crucial for millions of Americans who rely on insulin for diabetes management, as it addresses systemic issues in drug pricing and access. The changes mandated by the FTC could set a precedent for how pharmacy benefit managers operate, potentially leading to more equitable pricing structures in the future. As the healthcare landscape evolves, stakeholders will be closely monitoring the implementation of these changes and their impact on patient care and affordability.

STAT News/1d ago

insulin pricing / CVS Caremark / FTC settlement / pharmacy benefit managers / diabetes treatment

U.S. Drug Discount Program Sees $100 Billion in Sales Amid Controversy

In 2025, sales from the 340B Drug Discount Program in the United States reached $100 billion, marking a significant 22.8% increase from the previous year, according to data from the Health Resources and Services Administration (HRSA). This program mandates that pharmaceutical companies provide substantial discounts, typically ranging from 25% to 50%, on outpatient drugs to hospitals and clinics that cater primarily to low-income patients. The rising sales figures highlight the growing reliance on expensive medications within the program, with high-cost drugs accounting for approximately $61.9 billion, or nearly 62% of total expenditures. Keytruda, an immunotherapy treatment developed by Merck, emerged as the most purchased drug under the program, with nearly $8.9 billion spent on it. Following closely was Biktarvy, an HIV medication from Gilead Sciences, which saw expenditures exceeding $4.47 billion. These figures underscore the increasing financial burden of high-cost therapies on the healthcare system, particularly for facilities serving vulnerable populations. The implications of these rising costs are significant for healthcare providers and policymakers, as they navigate the balance between ensuring access to essential medications and managing the financial sustainability of the 340B program. As the program continues to grow, stakeholders will need to address the challenges posed by escalating drug prices and their impact on healthcare delivery for low-income patients. The future of the 340B program may hinge on ongoing discussions about drug pricing reforms and the role of government in regulating pharmaceutical costs.

STAT News · 1d ago

Record Surge in Cyclospora Infections Linked to Lettuce in Michigan and Other States

In 2026, the U.S. is experiencing a record surge in cyclospora infections, with over 4,700 cases reported, surpassing the previous high in 2019. The CDC has confirmed 1,645 cases since May 1, with Michigan, Ohio, Kentucky, and West Virginia identified as states with linked outbreaks. Michigan alone has reported over 3,300 cases, prompting health officials to investigate lettuce and salad greens as potential sources. Natasha Bagdasarian, Michigan's chief medical executive, noted that interviews with patients frequently mentioned lettuce, leading to recommendations for consumers to avoid bagged products and wash whole heads of lettuce thoroughly. The cyclospora parasite causes watery diarrhea and is typically treated with antibiotics. Outbreaks are more common in warmer months, often linked to contaminated produce. The CDC has acknowledged that many cases may go unreported due to mild symptoms, and the true number of infections could be higher. Federal health officials are conducting traceback investigations on multiple produce items, but have not confirmed any specific food vendors as sources. Taco Bell has temporarily removed certain ingredients as a precaution, although the FDA has not directly implicated any specific restaurant. As the summer progresses, health officials expect case numbers to continue rising, with the CDC monitoring the situation closely. The increase in cyclospora cases may be attributed to better detection methods and climate change, which can affect the spread of foodborne illnesses. The public is urged to remain vigilant and follow health guidelines to minimize the risk of infection.

STAT News · 1d ago

Democratic Senators Raise Concerns Over RFK Jr.'s Health Care Advisory Panel

Two prominent Democratic senators, Jeff Merkley and Ron Wyden, have expressed significant concerns regarding the credibility and potential conflicts of interest among members of the Healthcare Advisory Committee established by Health Secretary Robert F. Kennedy Jr. The committee, which aims to modernize the U.S. health care system, was announced in March and comprises 18 members selected from a pool of 400 candidates. Among those appointed are notable figures such as motivational coach Tony Robbins and various health care executives. The senators' letter, addressed to Kennedy and CMS Administrator Mehmet Oz, highlights the importance of ensuring that advisory panels are composed of individuals with appropriate qualifications and without financial conflicts that could undermine their recommendations. This scrutiny comes at a critical time as the U.S. health care system faces numerous challenges, including rising costs and access disparities. The outcome of this inquiry could influence future health policy decisions and the integrity of advisory committees in the health sector.

STAT News · 1d ago

Former Akero Team Launches Avere Therapeutics Focused on Immunology

The executive team from Akero Therapeutics, which was recently acquired by Novo Nordisk, has established a new biotech company named Avere Therapeutics, with backing from Fairmount. This venture aims to develop a long-acting oral drug targeting IL-23, which is intended for the treatment of psoriasis, ulcerative colitis, and other immunological conditions. The leadership team, including Andrew Cheng, Kitty Yale, and William White, previously developed a drug for non-alcoholic steatohepatitis (NASH) that contributed to Akero's $5 billion sale to Novo Nordisk. Avere Therapeutics is positioned to leverage the expertise gained from Akero's success in the biotech sector. The focus on IL-23 inhibitors is particularly relevant given the increasing prevalence of autoimmune diseases and the growing demand for effective treatments. The company aims to address significant unmet needs in the immunology space, which could potentially lead to improved patient outcomes. The launch of Avere Therapeutics highlights the ongoing trend of innovation in the biotech industry, particularly in the realm of immunology. As the company progresses, it will be essential to monitor its clinical development milestones and regulatory submissions, which will determine its impact on the market and patient care. Investors and healthcare professionals alike will be watching closely as Avere Therapeutics embarks on this new journey.

STAT News · 1d ago

Decline in Newborn Vitamin K Shots Raises Concerns Over Infant Health Risks

Prophylactic vitamin K injections for newborns have been a standard recommendation for over 50 years, crucial for preventing vitamin K deficiency bleeding, which can lead to severe health complications. However, a growing trend of parents opting out of this essential shot has raised alarms among healthcare professionals and lawmakers. A recent investigation by ProPublica highlighted the lack of tracking by the government on the uptake of these shots, suggesting that the number of preventable infant deaths due to vitamin K deficiency may be underestimated. A study published in JAMA Pediatrics underscores the risks associated with declining the vitamin K shot. In Sweden, the percentage of infants not receiving the shot rose from 0.66% in 2006 to 1.5% in 2021, correlating with a significant increase in bleeding incidents, including intracranial hemorrhages. This trend is concerning as it indicates a potential public health crisis, with lawmakers urging the CDC to monitor and report on vitamin K shot uptake to better understand its implications on infant health. The implications of this trend are profound, as the vitamin K shot is a simple and effective preventive measure that has saved countless lives. As awareness grows about the dangers of refusing this shot, healthcare providers are encouraged to engage in discussions with parents about the importance of vitamin K prophylaxis for newborns. Moving forward, it is critical for health authorities to implement tracking systems and educational campaigns to ensure that all newborns receive this vital intervention.

STAT News · 1d ago

Teva vs. Lilly: Appeals Court Revives Generic Drug Lawsuit Amid New Dementia Study Launch

A recent ruling by a U.S. appeals court has revived a lawsuit from Teva Pharmaceuticals against Eli Lilly, alleging a breach of agreement regarding the marketing of a generic version of Lilly's osteoporosis drug, Forteo. This decision overturns a previous ruling that deemed the agreement expired before Lilly's alleged breach. The legal battle began in 2016 when Lilly sued Teva for patent infringement, leading to a settlement in 2018 that allowed Teva to launch its generic drug in 2019, just prior to the expiration of Lilly's patents. However, Lilly was granted an additional three years of exclusivity by the FDA in 2020, prompting Teva to argue that this extension unlawfully delayed its product launch, resulting in a lawsuit filed in 2024. In a separate development, a significant clinical trial named PROTECT-Cog has been initiated to investigate the potential of lifestyle changes combined with GLP-1 agonists in reducing dementia risk. This study, backed by $100 million, was announced at the 2026 Alzheimer’s Association International Congress in London. It aims to enroll older adults at increased risk for cognitive decline and will compare two structured lifestyle-change programs—one intensive and another less rigid—both with and without drug treatment. Previous studies have indicated that lifestyle modifications can enhance cognitive function, making this trial particularly relevant as the population ages and dementia rates rise. The outcomes of both the Teva-Lilly lawsuit and the PROTECT-Cog study could have significant implications for the pharmaceutical industry and public health. The legal battle may affect the availability of generic osteoporosis treatments, while the dementia study could lead to new preventative strategies for cognitive decline, impacting millions of older adults worldwide.

STAT News · 1d ago

Concerns Raised Over FDA's Approval of Zyn Nicotine Pouches Amid Microplastics Risks

The FDA's approval of Zyn nicotine pouches has come under scrutiny following revelations from former FDA toxicologist Christy Leppanen. During her tenure at the FDA's Center for Tobacco Products, Leppanen conducted informal tests on Zyn pouches and raised alarms about the agency's understanding of the product's composition. Despite her concerns regarding the potential health risks associated with microplastics in the pouches, the FDA authorized their sale without fully investigating these issues. Leppanen's findings suggest that the pouches do not dissolve as previously claimed, which raises questions about the release of harmful particles during use. The nicotine pouch market is rapidly expanding, with projections indicating a 37% growth this year, reaching an estimated $6.8 billion. This growth is fueled by the tobacco industry's promotion of pouches as a safer alternative to traditional smoking. However, experts argue that the FDA's review process may not have adequately addressed the health implications of the pouch materials, which could potentially lead to microplastics entering the human body. Leppanen's allegations highlight a significant gap in the FDA's regulatory framework, as former officials emphasize the need for thorough evaluations of all product components before approval. The FDA has maintained that its review did not uncover new concerns regarding the ingredients of Zyn pouches, yet it has not disclosed specific information about the pouch materials. As the FDA continues to endorse Zyn, the implications for public health and regulatory practices remain a critical area of concern, especially as the agency faces pressure to balance the benefits of nicotine alternatives against potential risks to consumers.

STAT News · 1d ago

Deepfake Technology Poses New Threats to Trust in Healthcare Communications

Recent investigations have revealed the alarming rise of deepfake technology being used to impersonate healthcare professionals, leading to the promotion of unregulated products and misinformation. This issue is particularly concerning as it undermines the trust that patients place in their healthcare providers, which is essential for effective digital medicine. The phenomenon of deepfakes not only complicates the verification of identity but also threatens the integrity of clinical records and the evidence base in medical literature. As these synthetic media become more sophisticated, they create a landscape where patients may struggle to discern genuine medical advice from fabricated content. The implications of deepfake technology extend beyond individual patient encounters; they pose systemic risks to healthcare delivery. For instance, a voice-cloned physician could issue critical medication changes that may be acted upon without verification, potentially endangering patient safety. Moreover, the manipulation of medical images could compromise diagnostic accuracy, leading to misdiagnoses and inappropriate treatments. The potential for deepfakes to generate convincing yet fraudulent clinical trials raises concerns about the reliability of published medical research, further complicating the landscape of evidence-based medicine. To combat these threats, healthcare systems must establish a robust trust infrastructure that includes verification protocols and provenance tracking for clinical communications. Immediate steps can be taken, such as ensuring that critical information is communicated through secure channels and implementing callback verification for high-risk medical decisions. Training clinicians to address concerns about synthetic media and fostering open communication with patients about the authenticity of medical advice are also crucial. As the healthcare sector grapples with these challenges, a proactive approach to safeguarding trust and integrity in medical communications will be essential for maintaining patient safety and confidence in digital health solutions.

STAT News · 1d ago

Concerns Raised Over UnitedHealth's Medicare Advantage Diagnosis Audit Results

UnitedHealth Group has recently touted an audit claiming that 97% of diagnoses recorded for its Medicare Advantage members during home visits were justified by medical records. However, experts are questioning the validity and implications of these findings. The audit's results may not be as straightforward as the company suggests, raising concerns about the accuracy of the data and the potential impact on patient care and reimbursement processes. This situation is particularly significant as Medicare Advantage plans continue to grow in popularity, affecting millions of beneficiaries. Stakeholders, including healthcare providers and policymakers, are urged to scrutinize these findings to ensure that patient diagnoses are accurately represented and that the integrity of the Medicare Advantage program is maintained. As the healthcare landscape evolves, further investigations into such audits may be necessary to uphold standards and protect patient interests.

STAT News · 2d ago

Martha Lillard, Last U.S. Polio Patient Using Iron Lung, Passes Away at 78

Martha Lillard, the last known U.S. patient reliant on an iron lung due to polio, passed away on June 26 at the age of 78 in Oklahoma. Diagnosed with polio at age five, Lillard defied expectations of a short life, living independently for many years despite her condition. Her sister, Cindy McVey, attributes Lillard's death to complications from long-haul Covid-19, alongside chronic pulmonary failure and post-polio syndrome as noted on her death certificate. Polio, once a leading cause of paralysis in children, saw a dramatic decline in cases following the introduction of vaccines in 1955. The Centers for Disease Control and Prevention reported that the annual number of U.S. cases fell to fewer than 100 in the 1960s and fewer than 10 in the 1970s, leading to the disease's elimination in the U.S. by 1979. Lillard's life was marked by resilience; she adapted to her limitations through innovative means, including using a phone system to attend high school and engaging with the internet to connect with others. In her later years, Lillard faced significant health challenges, particularly during the Covid-19 pandemic, which severely impacted her already compromised lung capacity. Despite these struggles, she remained active in her passions, including writing and animal rescue. Lillard's story highlights the long-term effects of polio and the ongoing challenges faced by individuals with disabilities, especially in the context of new health crises like Covid-19. Her passing marks the end of an era for polio survivors in the U.S., as her family reflects on her legacy and the need for continued support for those affected by similar conditions.

STAT News · 2d ago

Biogen's Tau Therapy Data Sparks Interest at Alzheimer's Meeting

Recent discussions at a major Alzheimer's conference have highlighted the significance of Biogen's tau therapy, which is anticipated to provide new insights into treatment options for Alzheimer's disease. The therapy's potential to target tau proteins, which are implicated in the progression of Alzheimer's, has garnered attention from researchers and healthcare professionals alike. This comes at a time when the field is actively exploring innovative approaches to combat neurodegenerative diseases. Additionally, the U.S. Department of Health and Human Services (HHS) is developing national guidelines for the safe tapering of SSRIs, reflecting a broader focus on mental health treatments. Meanwhile, the FDA has approved Sanofi's wearable injector for a myeloma drug, indicating ongoing advancements in cancer therapies. The outcomes of these discussions and developments could significantly influence treatment protocols and patient care strategies moving forward.

STAT News · 2d ago

Caregivers Face Pay Cuts Amid Medicaid Budget Reductions, Raising Concerns Over Housing Stability

As states prepare to implement significant budget cuts under the Republicans’ One Big Beautiful Bill Act, family caregivers, particularly those caring for individuals with intellectual and developmental disabilities, are facing potential pay reductions. This legislation proposes a $1 trillion cut to Medicaid over the next decade, targeting programs that are not federally mandated. Reports indicate that at least six states are already moving to reduce compensation for these caregivers, who often cannot seek alternative employment due to their caregiving responsibilities. The emotional toll is profound, with some caregivers expressing fears of homelessness as they struggle to meet their families' needs. In a related development, a promising new drug for pancreatic cancer, Revolution Medicine’s daraxonrasib, has garnered significant attention at a recent conference in London. Preliminary clinical results suggest that patients treated with daraxonrasib lived nearly twice as long as those receiving standard chemotherapy in a study involving 500 participants. Although the drug has not yet undergone regulatory review, demand for access is high, raising concerns about potential costs and side effects, as well as the need for careful patient education regarding its limitations. Additionally, the Department of Health and Human Services is working on new clinical guidance for tapering patients off antidepressants, particularly SSRIs, following criticism of their overuse. This initiative aims to address the lack of training many healthcare providers have in this area, ensuring that patients receive informed support during the weaning process. Meanwhile, the appointment of Sean Kaufman, a vaccine skeptic, as Assistant Secretary for Preparedness and Response has sparked controversy, highlighting ongoing tensions in public health policy. These developments underscore the complex interplay between healthcare funding, caregiver support, and emerging treatments, all of which will require careful navigation as stakeholders respond to the evolving landscape of healthcare needs and policies.

STAT News · 2d ago

Maryland Caregivers Face Financial Crisis Amid Proposed Medicaid Wage Cuts

Family caregivers in Maryland are confronting severe financial challenges due to proposed wage cuts from the state's Medicaid program. The Maryland Department of Health's Developmental Disabilities Administration has suggested significant reductions in caregiver wages, with some facing cuts of up to $20 per hour. This decision, initially set to take effect on July 1, was postponed to October following advocacy from disability rights groups. Caregivers like Kristine Fifer, who has struggled to provide care for her son with cerebral palsy, express fears of bankruptcy or the need to institutionalize their loved ones, which often leads to higher risks of abuse and neglect. The situation in Maryland reflects a broader trend across several states, including Idaho, Indiana, Missouri, and Colorado, which are also proposing cuts to caregiver compensation as they prepare for impending Medicaid funding reductions tied to a GOP-backed tax bill set to take effect in 2027. Advocates warn that these cuts threaten the viability of home and community-based services, which are essential for many families relying on Medicaid waivers to manage care for individuals with intellectual and developmental disabilities. The proposed changes come amid a national conversation about the sustainability of Medicaid funding and the impact on vulnerable populations. The self-direction program, which allows families to manage their own care and receive compensation, has seen participation double over the past decade, indicating a growing reliance on this model. However, the financial strain on caregivers is exacerbated by rising living costs and the uncertainty of their income, leading many to reconsider their participation in the program. As the deadline for these cuts approaches, the future of family caregiving in Maryland and beyond hangs in the balance, with advocates calling for urgent action to protect these essential services.

STAT News · 2d ago

Dengue Virus Detected in Aedes aegypti Mosquitoes in Dubai: Implications for Public Health

A recent study conducted in Dubai, UAE, has confirmed the presence of dengue virus (DENV) in Aedes aegypti mosquitoes, highlighting a growing public health concern in the region. The research, part of an enhanced mosquito surveillance program by the Dubai Municipality, involved trapping mosquitoes across various urban settings from June 2024 to June 2025. A total of 3,743 adult mosquitoes were collected, with 1,598 identified as Aedes aegypti. Notably, DENV was detected in 5 out of 151 pools of Aedes aegypti, with both DENV-1 and DENV-2 strains identified. The significance of this finding lies in the increasing incidence of mosquito-borne diseases globally, exacerbated by climate change and urbanization. The UAE has seen a rise in dengue cases, particularly following periods of increased rainfall, which create favorable conditions for mosquito breeding. The study's results indicate that Aedes aegypti mosquitoes are now well-established in Dubai, primarily in labor camps and construction sites, raising concerns about potential outbreaks. The research utilized advanced molecular techniques to screen for various mosquito-borne viruses, including chikungunya and Zika, but DENV was the only virus detected in the sampled Aedes aegypti. The minimum infection rate for DENV was calculated at 3.1 per 1,000 mosquitoes, with detections occurring near key urban areas, including the main Dubai airport. This underscores the need for ongoing surveillance and public health interventions to mitigate the risk of dengue transmission in the region. As the study progresses, health authorities are urged to enhance vector control measures and public awareness campaigns to prevent potential outbreaks. The findings serve as a critical reminder of the evolving landscape of mosquito-borne diseases and the importance of proactive public health strategies in urban settings.

Emerging Inf. Dis. · 2d ago

Emerging Cases of Borrelia miyamotoi Disease Reported in Slovenia

Recent findings from Slovenia highlight the emergence of Borrelia miyamotoi disease, a tick-borne illness caused by the spirochete Borrelia miyamotoi, which has been increasingly recognized as a human pathogen since its first identification in ticks in Japan in 1995. The disease has been documented in various regions across the Northern Hemisphere, including Europe, where its prevalence in Ixodes ricinus ticks is estimated to be between 1% and 4%. In Slovenia, B. miyamotoi was detected in 2% of tested ticks and small rodents, with seroprevalence studies showing antibodies in an average of 4.4% of the population. The clinical presentation of B. miyamotoi disease typically includes acute febrile illness characterized by symptoms such as fatigue, headache, chills, myalgia, arthralgia, and nausea. Although it belongs to the relapsing fever group, recurrent febrile episodes occur in approximately 10% of cases. Notably, severe manifestations like meningoencephalitis have been reported primarily in immunocompromised individuals. As of March 2021, over 500 cases had been documented globally, with only a handful in Europe, indicating a potential underreporting of the disease in this region. In a recent study conducted at the University Medical Centre Ljubljana, two cases of B. miyamotoi disease were confirmed through advanced metagenomic sequencing techniques. Both patients presented with acute febrile illness and were diagnosed after standard laboratory tests failed to provide a clear diagnosis. The findings underscore the importance of awareness and diagnostic capabilities for B. miyamotoi disease, particularly in areas where tick populations are prevalent. As the understanding of this pathogen evolves, healthcare professionals are urged to consider B. miyamotoi in differential diagnoses for febrile illnesses, especially in patients with recent tick exposure.

Emerging Inf. Dis. · 2d ago

Surge of HPAI A(H5N1) Clade 2.3.4.4b D1.1 Virus Observed Across North American Flyways

The highly pathogenic avian influenza (HPAI) A(H5N1) clade 2.3.4.4b, specifically the D1.1 genotype, has shown a significant increase in prevalence across North America, particularly within the Pacific Flyway, since its initial detection in December 2021. This variant has been linked to widespread infections in wild birds, poultry, and even mammals, raising concerns about its zoonotic potential. Notably, there have been confirmed human infections, including a fatal case in Louisiana, highlighting the public health implications of this virus. Recent surveillance efforts by the Arizona Game and Fish Department have focused on monitoring the spread of the D1.1 genotype through targeted sampling of sick or deceased birds. The findings indicate that D1.1 has become the dominant lineage among HPAI infections in both wild and domestic avian populations. Phylogenetic analyses have been employed to trace the evolutionary history and diffusion patterns of this virus, revealing critical insights into its transmission dynamics across different flyway regions. The research utilized advanced genomic sequencing and bioinformatics tools to analyze over 660 virus genomes, providing a clearer picture of the virus's evolutionary rates and expansion timelines. The results underscore the importance of ongoing surveillance and research to understand the implications of HPAI A(H5N1) D1.1 for both animal and human health, as well as the need for preparedness in managing potential outbreaks. As the situation evolves, continued monitoring and research will be essential to mitigate the risks associated with this highly pathogenic virus and to inform public health responses effectively.

Emerging Inf. Dis. · 2d ago

Focus on Tau Protein Advances at Alzheimer’s Conference

The Alzheimer’s Association International Conference (AAIC) has brought renewed attention to tau proteins, which are critical in the pathology of Alzheimer’s disease. This year's conference highlights the latest research and developments in tau-targeted therapies, emphasizing their potential to alter the course of the disease. The significance of tau in Alzheimer’s has been underscored by recent studies showing its role in neurodegeneration and cognitive decline, making it a focal point for researchers and clinicians alike. The conference serves as a platform for sharing groundbreaking findings and fostering collaboration among scientists, healthcare professionals, and industry leaders. With an increasing number of clinical trials targeting tau, the outcomes could significantly impact treatment strategies for millions affected by Alzheimer’s. The urgency of addressing this neurodegenerative disease is underscored by the growing prevalence of dementia globally, with estimates suggesting that over 55 million people are currently living with dementia, a number expected to rise. As the conference progresses, attendees are encouraged to engage with the latest data and insights, which may pave the way for innovative approaches in dementia care. The emphasis on tau research not only highlights the scientific advancements but also reflects the ongoing commitment to improving patient outcomes in Alzheimer’s disease. Future developments in tau-targeted therapies could lead to new treatment paradigms, offering hope to patients and families grappling with the challenges of dementia.

STAT News · 3d ago

FDA Extends Deadline for Electric Shock Device Ban Amid Controversy

The FDA has postponed its decision on banning electrical stimulation devices used on individuals with intellectual disabilities and autism, missing its initial deadline in May. The new deadline is set for November, as the agency faces ongoing scrutiny over the use of these devices, which have been criticized as a form of torture by United Nations officials. Despite the controversy, the Judge Rotenberg Center in Massachusetts continues to utilize these devices, which have largely fallen out of favor in the U.S. The FDA had previously attempted to ban the practice in 2020, but a federal judge overturned this decision, highlighting the complex legal and ethical landscape surrounding the use of electrical stimulation for behavioral modification. The upcoming deadline will be closely watched by advocates and healthcare professionals concerned about the rights and treatment of vulnerable populations.

STAT News · 5d ago

Study Reveals Virulence Variability of Burkholderia pseudomallei Strains from the Americas and Africa

A recent study conducted by researchers from the US Army Medical Research Institute of Infectious Diseases and the CDC has examined the virulence of Burkholderia pseudomallei strains from the Western Hemisphere and Africa, particularly in mouse models. Melioidosis, the disease caused by this bacterium, has been recognized as an emerging public health threat in the United States, especially following its declaration as endemic in the Gulf Coast region in 2022. The study highlights the diverse virulence patterns exhibited by different strains, which could have significant implications for public health and biodefense strategies. The researchers tested 10 strains from the Americas and 3 from Ghana, assessing their growth in culture and biofilm formation, as well as determining the 50% lethal dose (LD50) in BALB/c and C57BL/6 mouse models. The findings revealed that while the strains grew similarly in culture, they displayed notable differences in biofilm production and virulence, with some causing rapid disease onset and others leading to delayed fatal outcomes. This variability underscores the need for tailored medical countermeasures against diverse B. pseudomallei strains. Melioidosis is often underreported due to its varied clinical manifestations and the lack of awareness among healthcare providers in non-endemic regions. The study's results are crucial as they contribute to the understanding of B. pseudomallei's global distribution and its potential to cause outbreaks in areas previously considered low-risk. As the disease continues to emerge in the U.S. and other regions, ongoing research is essential to develop effective diagnostics and treatments, particularly in light of recent cases linked to imported products and local transmission events. The implications of this research extend beyond academic interest; they are vital for informing public health policies and preparedness strategies in the face of an evolving infectious disease landscape. Future studies will likely focus on further characterizing these strains and evaluating the effectiveness of existing and new therapeutic interventions.

Emerging Inf. Dis. · 5d ago

New Biomarkers Enhance Diagnosis of Enteric Fever in South Asia

Recent research has demonstrated the effectiveness of using antibodies to Salmonella enterica serovar Typhi hemolysin E (HlyE) and lipopolysaccharide (LPS) IgA for identifying enteric fever cases in South Asia, specifically in Bangladesh, Nepal, and Pakistan. Traditional diagnostic methods for enteric fever, caused by Salmonella Typhi and Paratyphi, have been criticized for their lack of accuracy, affordability, and efficiency. The study evaluated the performance of these biomarkers in distinguishing enteric fever cases from other febrile illnesses, achieving an impressive area under the receiver operating characteristic curve (AUC) of 0.93 when combining both biomarkers, with a specificity of 86% at a fixed sensitivity of 90%. Notably, in children under five, the combined biomarkers showed even higher performance (AUC 0.96). The significance of this research lies in its potential to improve diagnostic accuracy in regions where enteric fever is endemic, particularly in settings with inadequate sanitation where the disease is prevalent. Current diagnostic methods, such as blood cultures, are often slow, expensive, and not widely accessible, leading to delays in treatment. The findings suggest that HlyE and LPS IgA-based assays could serve as reliable alternatives for rapid diagnosis, thereby facilitating timely intervention and management of enteric fever cases. The study involved participants from various hospitals across South Asia, with data collected from October 2017 to June 2022. This multisite approach strengthens the validity of the findings and highlights the need for further research to implement these biomarkers in clinical settings. As healthcare professionals seek more effective diagnostic tools, the integration of HlyE and LPS IgA assays could represent a significant advancement in the fight against enteric fever in endemic regions.

Emerging Inf. Dis. · 5d ago

Whistleblower Challenges Health Insurance Practices Amid Rising Costs and FDA Leadership Changes

In a recent episode of STAT's podcast 'The Readout LOUD,' the discussion centered around the escalating costs of health insurance and the implications for American families and small businesses. Bob Herman, a STAT reporter, highlighted his new series 'Out of Pocket, Out of Reach,' which investigates how soaring health insurance costs are impacting access to care. The series reveals that the financial burden of family health insurance can rival the cost of purchasing a new car, raising concerns about affordability and accessibility in the healthcare system. The episode also features Chris Deacon, a whistleblower who has filed a lawsuit against an insurance contractor for allegedly violating contracts related to health benefits for New Jersey state workers. This case underscores the ongoing issues within the insurance industry and the need for accountability in health benefit management. Additionally, the podcast touches on significant developments in the life sciences sector, including Anthropic's entry into drug development and Vertex Pharmaceuticals' largest acquisition to date. These advancements reflect the dynamic nature of the biotech industry and the potential for innovative treatments. As the healthcare landscape evolves, the appointment of a new FDA commissioner is also on the horizon, with implications for regulatory practices and drug approvals. The discussions in this episode highlight the interconnectedness of insurance costs, regulatory changes, and the future of drug development, making it a critical time for stakeholders in the healthcare sector to stay informed and engaged.

STAT News · 6d ago

ARPA-H Allocates $160 Million for Custom Gene Editing Drug Development

The Advanced Research Projects Agency for Health (ARPA-H) has announced a significant investment of up to $160 million aimed at advancing custom gene editing therapies for various rare diseases. This initiative, named THRIVE, will support seven research teams over a five-year period, each focusing on different conditions that impact various organ systems. The goal is to replicate the success seen in cases like that of Baby KJ, a patient who benefited from innovative gene editing treatments. Each team involved in the THRIVE program is expected to initiate clinical trials by the third year of the project, with some potentially starting even earlier. This funding is part of ARPA-H's broader mission to accelerate health research and develop transformative medical solutions. The emphasis on rare diseases highlights the agency's commitment to addressing unmet medical needs in populations that often lack effective treatment options. The implications of this funding are significant for patients suffering from rare genetic disorders, as successful outcomes could lead to groundbreaking therapies that not only improve individual health outcomes but also pave the way for future innovations in gene editing. As the program progresses, the healthcare community will be closely monitoring the advancements and results from these clinical trials, which could reshape the landscape of genetic medicine.

STAT News · 6d ago

OpenEvidence Study Challenges Previous Findings on AI in Healthcare

Recent research supported by OpenEvidence has emerged, presenting findings that challenge a prominent study released weeks prior regarding the efficacy of artificial intelligence (AI) in healthcare settings. This new study suggests that the AI models previously deemed superior may not perform as well as claimed, raising important questions about the reliability of AI technologies in clinical applications. The implications of this research are significant, as healthcare professionals increasingly rely on AI tools for decision-making and patient care. The study's findings are particularly relevant in the context of ongoing discussions about the regulation of AI by the FDA and its integration into Medicare reimbursement frameworks. As healthcare technology continues to evolve, understanding the true capabilities and limitations of AI systems is crucial for ensuring patient safety and effective treatment outcomes. This research could influence future regulatory decisions and the adoption of AI technologies in clinical practice. Healthcare providers, policymakers, and technology developers are all stakeholders in this conversation, as the outcomes of such studies can directly impact patient care strategies and the allocation of resources in healthcare settings. The ongoing debate highlights the need for rigorous evaluation of AI tools before widespread implementation. Looking ahead, further investigations and peer-reviewed studies will be essential to clarify the role of AI in healthcare and to establish best practices for its use. As the landscape of health technology continues to shift, staying informed about these developments will be vital for all professionals involved in patient care and health technology innovation.

STAT News · 6d ago

The Importance of Safe Cannabis Use Among Seniors: A Call for Medical Guidance

As cannabis use becomes increasingly common among older adults, healthcare professionals must prioritize education on safe consumption practices. A significant demographic shift has been observed, with 25.8% of medical cannabis patients in New York being aged 65 or older. This trend highlights the need for doctors to understand the implications of cannabis use in this population, particularly as many seniors turn to cannabis for relief from chronic pain, anxiety, and insomnia. While cannabis can improve health-related quality of life and reduce reliance on traditional pharmaceuticals, the potency of modern cannabis poses risks, especially for older adults who may have diminished liver and kidney function. The potency of cannabis has increased dramatically over the past decades, making it essential for healthcare providers to guide patients on appropriate dosages. Overconsumption can lead to uncomfortable experiences, though it is generally not lethal. The cannabis industry is divided, with some small businesses focusing on ethical practices while larger corporations prioritize profit, often producing high-THC products that may inadvertently appeal to younger audiences. This raises concerns about the potential normalization of high-potency cannabis among adolescents, despite overall teenage usage remaining stable post-legalization. To ensure the safe use of cannabis among seniors, healthcare providers must engage in ongoing education about medical marijuana. This includes understanding the principle of 'start low and go slow' to prevent adverse effects. Additionally, there is a call for the cannabis industry to focus on breeding strains with lower THC and higher medicinal cannabinoids to better serve medical patients. Legalization at the federal level could enhance product quality and safety, ultimately benefiting millions of medical cannabis users across the country. The need for informed practitioners and educated patients is critical to maximizing the therapeutic benefits of cannabis while minimizing risks.

STAT News · 6d ago

MAHA Mondays Highlight Health Initiatives at the Great American State Fair

The Great American State Fair in Washington recently concluded its two-week event, which prominently featured two 'MAHA Mondays' dedicated to the Make America Healthy Again (MAHA) movement. These sessions included discussions led by key figures in health policy, including Health and Human Services senior adviser Calley Means and acting Surgeon General Stephanie Haridopolos. The focus of these discussions was on integrating health and wellness into the American identity, emphasizing the importance of public health initiatives in shaping societal norms. During the second MAHA Monday, Means highlighted the significance of community engagement in promoting healthier lifestyles, while Haridopolos addressed the recent advisory from the Surgeon General regarding the negative impacts of excessive screen time on health. This advisory is particularly relevant as it aligns with growing concerns about mental health and well-being in the digital age, affecting a wide demographic, especially children and adolescents. The MAHA movement aims to foster a culture of health awareness and proactive wellness strategies across the nation. By bringing together health officials and the public, the initiative seeks to inspire actionable change and encourage individuals to prioritize their health. As the fair wraps up, the discussions from MAHA Mondays are expected to resonate beyond the event, influencing future health policies and community programs. Looking ahead, the MAHA movement plans to continue its outreach efforts, potentially expanding its initiatives to include more public forums and educational resources aimed at improving health literacy and access to wellness programs across the country.

STAT News · 6d ago

Debate Intensifies Over Classifying Obesity as a Disease Amidst New Drug Approvals

The classification of obesity as a disease is gaining traction as pharmaceutical companies like Eli Lilly and Novo Nordisk promote this narrative alongside the launch of new anti-obesity medications. Eli Lilly's website emphasizes that obesity is a chronic medical condition, while Novo Nordisk cites the World Health Organization's recognition of obesity as a disease. This framing is significant as it legitimizes the need for medical interventions, particularly in light of the rising prevalence of obesity and its associated health risks, including cardiovascular disease and type 2 diabetes. Despite the compelling arguments for classifying obesity as a disease, the medical community remains divided. The American Medical Association (AMA) has previously noted the lack of a clear definition of disease and questioned whether recognizing obesity as a disease would lead to improved health outcomes. The AMA's deliberations highlighted the potential implications of such a classification, including changes in insurance coverage, treatment approaches, and societal perceptions of obesity. The ongoing debate raises critical questions about who benefits from this classification. While GLP-1 drugs like Wegovy and Mounjaro have shown promise in aiding weight loss and improving cardiovascular health, there are concerns that emphasizing a biological perspective may overshadow behavioral and environmental interventions. The recent fines imposed on Novo Nordisk and Eli Lilly for their direct-to-consumer campaigns underscore the regulatory scrutiny surrounding the marketing of obesity treatments. As the landscape of obesity treatment evolves, healthcare professionals must navigate the complexities of disease classification, ensuring that it does not detract from holistic approaches to obesity management. The implications of labeling obesity as a disease extend beyond clinical practice, influencing research funding, public health strategies, and the overall understanding of this multifaceted condition.

STAT News · 6d ago

Study Reveals Hantavirus Exposure in Northwestern Italy: Implications for Public Health

A recent study conducted in northwestern Italy from 2004 to 2018 has uncovered serologic evidence of hantavirus exposure among humans, highlighting a previously underexplored area for rodent-borne viruses. The research, involving 371 patients from the provinces of Novara, Biella, Vercelli, and Verbano Cusio-Ossola, found that 27 individuals (7.3%) tested positive for hantavirus IgG, with a significant prevalence of Puumala virus (PUUV) neutralizing antibodies. This finding is particularly noteworthy as hantavirus infections are rarely diagnosed in Italy, despite being reported in neighboring countries such as France and Austria. The study's participants, with an average age of 59.9 years, included individuals with various chronic conditions, which may have implications for understanding the risk factors associated with hantavirus exposure. The seropositivity rate of 7.3% in this study is considerably higher than the previously reported 0.2% for Dobrava-Belgrade virus (DOBV) among forestry workers in Trentino, suggesting a potential increase in hantavirus circulation in the region. Additionally, the study found that 10 out of 371 patients (2.7%) were positive for lymphocytic choriomeningitis virus (LCMV), aligning with previous findings from other areas in Italy. The geographical distribution of seropositive cases was concentrated in Novara, indicating localized exposure risks. The predominance of PUUV-specific neutralizing activity suggests that this virus is the likely cause of infection among the seropositive individuals. The study emphasizes the need for increased awareness and monitoring of hantavirus and LCMV in Italy, particularly in regions with known rodent populations. Future research should focus on longitudinal studies to better understand the epidemiology of these viruses and their potential health impacts on the population.

Emerging Inf. Dis. · 6d ago

Finalists for FDA Leadership Under White House Review

The White House is currently reviewing the top candidates to lead the Food and Drug Administration (FDA), with three finalists identified: Heidi Overton, a White House adviser; Jeffrey Vacirca, an oncologist and health system executive; and Stephen Ferrara, a health affairs official at the Department of Defense. This decision is critical as the FDA plays a pivotal role in regulating food and drug safety, impacting public health and the pharmaceutical industry. The selection of a new FDA leader is particularly significant given the ongoing discussions around drug approval processes, vaccine distribution, and regulatory reforms in the wake of the COVID-19 pandemic. The chosen candidate will need to navigate complex health policies and address the challenges posed by corporate influence in healthcare. The final decision from the White House is anticipated soon, which will set the direction for the FDA's future initiatives and priorities.

STAT News · Jul 8

Affordable Care Act Insurers Propose Significant Premium Increases Amid Enrollment Decline

In a concerning trend for healthcare affordability, many insurers participating in the Affordable Care Act (ACA) are proposing double-digit premium increases for 2027, with a median rate hike of 14% reported across 16 states and the District of Columbia. This marks the second consecutive year of substantial premium increases, primarily driven by rising medical costs and recent policy changes. The proposed increases could represent the second-highest since 2018, compounding financial pressures on consumers who have already faced higher premiums in 2026 and the expiration of enhanced tax credits. The Biden administration had previously sought to strengthen the ACA by increasing tax subsidies, which successfully lowered out-of-pocket costs and boosted enrollment to over 20 million Americans. However, the expiration of these subsidies, coupled with policy shifts under the Trump administration, has led to a significant drop in enrollment, with approximately 3 million fewer individuals enrolled compared to the previous year. Experts suggest that the rising costs are driving healthier individuals to forgo insurance, leaving a higher proportion of older and sicker enrollees, which could further escalate costs for insurers. Insurers attribute part of the proposed premium increases to the lasting effects of the expired subsidies and policy changes that may complicate enrollment processes. Additionally, there is a noted increase in the severity of claims, potentially due to both a rise in patient illness and the use of artificial intelligence by healthcare providers to optimize billing practices. As a result, individuals with incomes just above 400% of the federal poverty level, who are no longer eligible for subsidies, will be particularly affected by these premium hikes. Looking ahead, consumers may need to explore different plans during the upcoming enrollment period in October to mitigate the impact of rising premiums. The situation underscores the ongoing challenges within the ACA framework and the need for policy interventions to stabilize the market and protect consumers from escalating healthcare costs.

STAT News · Jul 8

Lung Transplants Show Promise for Stage 4 Lung Cancer Patients in New Study

A groundbreaking study from Northwestern Medicine has revealed that double lung transplants can significantly extend survival for patients with stage 4 lung cancer that has not metastasized beyond the lungs. Traditionally, patients with advanced lung cancer have been deemed unsuitable for transplants due to high recurrence rates and low survival outcomes. However, the study, published in JAMA, followed 404 patients with end-stage pulmonary disease, including 98 with stage 4 lung cancer, and found that those who received lung transplants had a one-year survival rate of 100%, compared to 88% for those receiving standard treatments like chemotherapy and immunotherapy. The research involved 17 patients who underwent lung transplants after rigorous selection processes ensured their cancer was confined to the lungs. Among these patients, four experienced cancer recurrence and two died from unrelated causes. In contrast, 74 out of 81 patients receiving standard care saw their cancer progress. The study's lead author, Dr. Ankit Bharat, emphasized the importance of patient selection and improved surgical techniques, drawing on lessons learned from performing lung transplants in COVID-19 patients. Despite the promising results, experts caution that ethical considerations must be addressed before this approach can be widely adopted. The allocation of donor organs is a zero-sum game, meaning each transplant for a cancer patient could deny another patient in need. The study's findings suggest that with careful patient selection, lung transplants could be a viable option for select stage 4 lung cancer patients, but further research is needed to confirm these results in larger, randomized trials. Currently, it is estimated that around 300 patients in the U.S. are diagnosed with stage 4 non-small cell lung cancer that has not spread beyond the lungs each year. One such patient, Jodi Graf, a 61-year-old robotic software engineer, was able to receive a lung transplant after her cancer was confirmed to be localized. Her experience highlights the potential for lung transplants to offer new hope for patients facing dire prognoses, but the medical community must navigate the complex ethical landscape surrounding organ transplantation.

STAT News · Jul 8

Europe to Expedite Review of RevMed's New Drug Amid Growing Biotech Developments

The European regulatory authorities have announced an accelerated review process for RevMed's latest drug, a significant move in the context of the rapidly evolving biotech landscape. This decision comes as the industry witnesses a surge in innovative treatments, particularly in the obesity sector, and reflects a broader trend of adapting regulatory frameworks to keep pace with scientific advancements. The urgency of this review underscores the importance of timely access to new therapies for patients, especially as obesity rates continue to rise across Europe. RevMed's drug is part of a growing portfolio of obesity treatments that have gained attention for their potential to address a pressing public health issue. With obesity linked to numerous comorbidities, including diabetes and cardiovascular diseases, the implications of this drug's approval could be far-reaching. The expedited review process aims to ensure that effective treatments reach patients more quickly, potentially improving health outcomes and reducing the burden on healthcare systems. In addition to RevMed's developments, the biotech sector is also witnessing significant changes in drug payment models and the emergence of psychedelics as a therapeutic option. These trends highlight the dynamic nature of the industry and the need for regulatory bodies to adapt to new challenges and opportunities. As the review progresses, stakeholders will be closely monitoring the outcomes, which could set precedents for future drug approvals in Europe. As the situation unfolds, healthcare professionals and industry experts are encouraged to stay informed about the latest developments in drug approvals and regulatory changes that may impact patient care and treatment options. The ongoing evolution of the biotech landscape necessitates a proactive approach to understanding the implications of these advancements.

STAT News · Jul 8

FDA Approves Vera's Trutakna for IgA Nephropathy; U.K. Nears Enhertu Pricing Agreement

The FDA has granted approval for Trutakna, a new treatment for IgA nephropathy developed by Vera Therapeutics. This condition, characterized by the accumulation of immune antibodies in the kidneys, affects a significant number of patients, and Trutakna is one of several new therapies entering the market. The annual cost of Trutakna is set at $425,000 before insurance discounts, raising concerns about affordability and access for patients. Meanwhile, in the U.K., officials are close to finalizing a pricing agreement for Enhertu, a breast cancer treatment from AstraZeneca and Daiichi Sankyo. Enhertu has demonstrated the potential to extend survival by approximately six months for certain patients. This development follows a reassessment of drug pricing metrics in the U.K., which previously deemed Enhertu not cost-effective. The outcome of these negotiations could significantly impact access to this life-extending therapy for women in England and Wales, highlighting ongoing challenges in balancing drug costs with patient access to innovative treatments.

STAT News · Jul 8

The Crucial Role of Human Accountability in the AI Licensure Debate

The ongoing discussion surrounding AI licensure in healthcare is missing a critical element: human accountability. As AI technologies increasingly influence clinical decision-making, the responsibility for patient outcomes remains firmly with physicians. This dynamic raises important questions about who is held accountable when AI-generated recommendations lead to adverse outcomes. The authors, Afnan R. Tariq and Ami Bhatt, emphasize that licensure is not merely a credential but a reflection of a physician's obligation to their patients. Historical legal precedents underscore that the duty to disclose risks and make informed decisions cannot be delegated to machines or systems. As AI continues to evolve in the medical field, it is essential that physicians maintain their role as the ultimate decision-makers, ensuring that accountability remains intact. The integration of AI into cardiology and other specialties must be guided by the principle that human judgment and responsibility are paramount in patient care, reinforcing the essence of professionalism in medicine.

STAT News · Jul 8

FDA Approves Vera Therapeutics' Trutakna for IgA Nephropathy Treatment

The FDA has granted approval to Vera Therapeutics for Trutakna, a new treatment for IgA nephropathy, a chronic autoimmune kidney disease. This condition is characterized by the accumulation of immune antibodies in the kidneys, leading to progressive kidney function loss and potential organ failure requiring dialysis. The approval marks a significant advancement in the management of IgAN, which has garnered increasing attention from biotech firms due to its serious health implications. Vera Therapeutics' CEO, Marshall Fordyce, expressed enthusiasm about the approval, emphasizing the importance of bringing Trutakna to patients suffering from this debilitating condition. The approval is expected to provide new hope for those affected by IgAN, a disease that has limited treatment options and can lead to severe health complications. With the introduction of Trutakna, healthcare professionals will have a new therapeutic option to consider for managing IgA nephropathy, potentially improving patient outcomes and quality of life. The market response and subsequent studies will be closely monitored as the drug becomes available to patients, paving the way for further innovations in the treatment of autoimmune kidney diseases.

STAT News · Jul 7

Challenges Facing the Employer-Based Health Insurance System in the U.S.

The employer-based health insurance system in the United States is facing significant challenges, impacting both workers and businesses. A recent analysis highlights the increasing financial burden on employers and employees, as healthcare costs continue to rise. This trend is concerning as it threatens the accessibility and affordability of health insurance for millions of Americans. The implications of a crumbling employer-based system could lead to a shift in how health insurance is provided, potentially increasing reliance on government programs or alternative models. Stakeholders in the healthcare sector, including policymakers and business leaders, must address these issues to ensure sustainable healthcare coverage moving forward.

STAT News · Jul 7

Vertex Pharmaceuticals Acquires Crinetics for $10 Billion to Expand Rare Disease Portfolio

Vertex Pharmaceuticals has announced its largest acquisition to date, agreeing to purchase Crinetics Pharmaceuticals for $10 billion. This strategic move aims to enhance Vertex's portfolio in the treatment of rare endocrine disorders, a growing area of focus in the biotech industry. The acquisition underscores the increasing competition and investment in the biotech sector, particularly as companies seek to innovate and expand their therapeutic offerings. The deal is significant not only for Vertex but also for the broader healthcare landscape, as it reflects a trend of consolidation among biotech firms. With rising health insurance costs and a surge in new drug payment models, companies are under pressure to deliver effective treatments while managing financial sustainability. The acquisition of Crinetics, known for its development of therapies targeting rare diseases, positions Vertex to potentially lead in this niche market. Healthcare professionals and stakeholders should monitor the implications of this acquisition, as it may influence drug pricing, access to treatments, and the overall market dynamics in the biotech industry. As Vertex integrates Crinetics' assets, the focus will likely shift towards the development and commercialization of new therapies, which could benefit patients with rare endocrine disorders. The next steps for Vertex will involve regulatory approvals and strategic planning to maximize the potential of this acquisition.

STAT News · Jul 7

Study Investigates Telehealth Services for GLP-1 Medications

A recent study has examined the quality and accessibility of telehealth services offering GLP-1 medications, which are increasingly used for managing obesity and type 2 diabetes. This investigation is crucial as telehealth has become a popular alternative for patients seeking weight management solutions, especially in the wake of the COVID-19 pandemic. The findings highlight the variability in service quality across different telehealth platforms, raising concerns about patient safety and the effectiveness of remote consultations. The study's implications are significant for healthcare providers and patients alike. With the rising prevalence of obesity and diabetes, understanding the reliability of telehealth services is essential for ensuring that patients receive appropriate care. Key data from the study indicate that while some platforms provide comprehensive consultations, others may lack necessary follow-up and monitoring, which are critical for the safe administration of GLP-1 medications. As telehealth continues to evolve, stakeholders in the healthcare industry must address these disparities to enhance service delivery. Future efforts may include establishing standardized protocols for telehealth consultations and improving regulatory oversight to ensure that all patients have access to high-quality care. This study serves as a call to action for healthcare professionals to advocate for better telehealth practices and for patients to remain informed about the services they choose.

STAT News · Jul 7

Concerns Rise Over Potential Endemic Ebola Outbreak in DRC Amid Weakened Global Health Response

A new Ebola outbreak in the eastern Democratic Republic of Congo (DRC) raises alarms about the potential for the virus to become endemic, as historical containment strategies falter. Experts Ivan Buendia Gayton and Eric D. Perakslis highlight that the current outbreak is occurring in densely populated areas, complicating traditional methods of outbreak control. Unlike previous outbreaks, which were often contained through international cooperation and local adaptations, the current global health landscape is marked by reduced funding and a shift towards isolationist policies. The authors emphasize that the DRC's outbreak is exacerbated by ongoing regional conflicts and economic changes that facilitate the rapid movement of people and goods, increasing the risk of the virus spreading beyond its current borders. With no proven medical countermeasures for the Bundibugyo strain of Ebola and weakened capacities of organizations like the World Health Organization and the Centers for Disease Control and Prevention, the situation is dire. The potential for an uncontained outbreak poses a significant threat not only to Central Africa but also to global health security. If the outbreak is not effectively managed, it could lead to a permanent Ebola frontier, resulting in ongoing suffering and destabilization. The authors call for renewed commitment and resources to prevent this scenario, stressing that the world must act decisively to stop the outbreak before it becomes a chronic issue.

STAT News · Jul 7

Small Businesses in America Abandoning Health Insurance Amid Rising Costs

A growing number of small businesses in the United States are discontinuing health insurance offerings for their employees, reflecting a significant shift in the employer-based health insurance landscape. This trend is particularly alarming as the percentage of working-age adults receiving health coverage through their jobs has dropped from 67% in 1998 to approximately 60% today. The rising costs associated with health insurance, driven by escalating premiums, hospital fees, and prescription drug prices, are placing immense financial strain on small business owners and their employees. Interviews conducted with over 50 stakeholders, including small business owners, employees, and health policy experts, reveal a pervasive sense of panic and frustration. Many small businesses feel that the available health insurance options are increasingly unaffordable, particularly those with high out-of-pocket expenses. As a result, these businesses are opting to eliminate traditional health benefits at an unprecedented rate, undermining the long-standing expectation that employment provides health protection. This shift not only threatens the financial stability of small businesses but also raises concerns about the overall health security of American workers. The implications of this trend could lead to a broader public health crisis, as individuals may forgo necessary medical care due to lack of insurance. Moving forward, it is crucial for policymakers to address the underlying issues driving these cost increases and to explore alternative solutions that can sustain health coverage for small businesses and their employees.

STAT News · Jul 7

Filovirus Surveillance in Cameroon Following Marburg Outbreak in Equatorial Guinea

In response to the Marburg virus disease (MVD) outbreak declared in Equatorial Guinea on February 13, 2023, researchers conducted a comprehensive One Health surveillance study in southern Cameroon, particularly in communities bordering the affected region. The outbreak, which resulted in 15 confirmed cases and a staggering 73% case-fatality rate, raised concerns about the potential spillover of the virus into Cameroon due to extensive cross-border movements. The study aimed to assess the risk of filovirus circulation through human seroprevalence surveys, bat sampling, and environmental investigations. During July and August 2023, researchers enrolled 181 participants from 14 villages in the Olamze district, documenting symptoms and potential exposures to MARV. The findings revealed that 1.7% of participants were seropositive for MARV, with additional seropositivity observed for other filoviruses, including Ebola and Sudan viruses. Notably, the study highlighted the significant interactions between local communities and wildlife, with 45% of participants reporting recent animal contact, including with bats, which are known reservoirs for the virus. The results underscore the importance of ongoing surveillance and public health preparedness in regions at risk of filovirus outbreaks. The small sample size limits the ability to draw definitive conclusions about risk factors, but the presence of MARV antibodies in the community indicates a need for heightened awareness and preventive measures. Future research will be crucial in understanding the dynamics of filovirus transmission and in developing strategies to mitigate the risk of outbreaks in Cameroon and neighboring countries.

Emerging Inf. Dis. · Jul 7

Vertex Pharmaceuticals Acquires Crinetics for $10 Billion, Expanding Rare Disease Portfolio

Vertex Pharmaceuticals has announced a significant acquisition of Crinetics Pharmaceuticals for $10 billion, marking the largest deal in Vertex's history. This acquisition includes Crinetics' commercial drug, Palsonify, which was launched last year to treat acromegaly, a rare endocrine disorder. The deal also encompasses other promising drug candidates in Crinetics' pipeline, including a therapy for congenital adrenal hyperplasia, which is currently in late-stage development. The acquisition price of approximately $85 per share reflects a strong market confidence in Crinetics, as evidenced by a 101% surge in its stock price during after-hours trading following the announcement. This move is part of a broader trend in the biotech sector, where mergers and acquisitions are becoming increasingly common as companies seek to bolster their portfolios with innovative therapies. This acquisition is particularly significant for healthcare professionals and stakeholders in the rare disease community, as it highlights the growing investment in treatments for conditions that have limited therapeutic options. The integration of Crinetics' assets into Vertex's operations could accelerate the development and commercialization of new therapies, potentially benefiting patients with rare endocrine disorders in the near future.

STAT News · Jul 6

Study Reveals Rapid Online Prescriptions for GLP-1 Medications Lack Clinical Oversight

A recent secret shopper study involving 49 telehealth websites has highlighted significant concerns regarding the prescription practices for GLP-1 medications, such as semaglutide and tirzepatide, which are increasingly sought after for weight loss. The study, published in the Journal of the American Medical Association, was conducted by a researcher from Yale University who posed as a patient to assess the ease of obtaining these prescriptions online. The findings indicate that patients can acquire GLP-1 prescriptions with remarkable speed and minimal clinical oversight, raising alarms among healthcare professionals about the potential risks associated with such practices. The surge in demand for GLP-1 medications has been exacerbated by recent shortages, leading to the emergence of compounded versions that lack FDA approval. This trend underscores the growing consumerization of healthcare, particularly in the realm of telehealth, where convenience often trumps thorough clinical evaluation. Experts are concerned that the lack of stringent oversight in virtual care could compromise patient safety and treatment efficacy. As telehealth continues to evolve, it is crucial for healthcare providers and regulatory bodies to address these challenges. The findings from this study may prompt further investigation into the practices of telehealth companies and could lead to calls for enhanced regulations to ensure patient safety in the digital health landscape. Stakeholders in the healthcare sector must remain vigilant to balance the benefits of accessibility with the necessity of clinical rigor.

STAT News · Jul 6

Anthropic CEO Discusses AI's Future Impact on Biotech at Recent Event

During a recent event, Dario Amodei, CEO of Anthropic, shared insights on the anticipated impact of artificial intelligence (AI) on the biotech sector. While he previously suggested that AI could accelerate research progress significantly, he now acknowledges that such advancements may take longer than expected. Amodei highlighted that current AI models are not yet capable of delivering the transformative results envisioned, citing limitations in model performance, the need for researchers to adapt to new tools, and the slow evolution of regulatory frameworks. This conversation took place at the unveiling of Claude Science, a new product aimed at aiding biologists and pharmaceutical companies in their research efforts. The discussion underscores the cautious optimism surrounding AI's role in biotech, emphasizing that while the potential is vast, the timeline for realizing these benefits may extend beyond initial projections. As the industry navigates these challenges, stakeholders will need to focus on developing the necessary infrastructure and regulatory support to harness AI's full capabilities in the future.

STAT News · Jul 6